Research programme: cardiovascular disorder therapeutic - Penwest Pharmaceuticals
Alternative Names: PW4105Latest Information Update: 20 Aug 2009
At a glance
- Originator Penwest Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 17 Oct 2003 Preclinical trials in Cardiovascular disorders in USA (unspecified route)